ASPAVELI 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0002 
Update of sections 4.2, 4.8,  5.1, 5.2 of the SmPC 
19/05/2022 
SmPC  and PL 
Update of sections 4.4, 4.8,  5.1, 5.2 of the SmPC  to reflect 
based on final results from study APL2-302 
(Pegasus) listed as a category 3 study in the RMP; 
this is a global, Phase 3, prospective, randomised, 
multicentre, open-label, active-comparator–
controlled study in 80 subjects. The objective was to 
efficacy and safety results from the final study APL2-302, 
including the 48 weeks data. 
Results of the key efficacy analyses of (OLP)  confirm the 
results observed during the 16-week randomized 
completion phase (RCP)  and suggest an improvement in 
1 Notifications are issued for type I  variations and Article 61(3) notifications (unless part of a group including a type II  variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II,  labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC  (Summary  of Product Characteristics), Annex II,  Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union 
 
 
 
 
 
 
  
 
 
 
confirm treatment efficacy and safety of 
pegcetacoplan monotherapy for the treatment of 
Paroxysmal Nocturnal Hemoglobinuria (PNH). The 
submission of this study addresses MEA 001. The 
Package Leaflet is updated accordingly. The RMP 
version 1.0 has been agreed. 
C.I.4  - Change(s) in the SPC,  Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Paroxysmal Nocturnal Hemoglobinuria (PNH) markers. The 
PK analysis within OLP  showed that therapeutic 
concentrations of pegcetacoplan were maintained for up to 
Week 48.  
The Package Leaflet (PL) was updated accordingly. 
For more information, please refer to the Summary of 
Product Characteristics. 
IB/0003 
B.II.f.1.b.1  - Stability of FP  - Extension of the shelf 
21/02/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0001 
B.II.b.1.a  - Replacement or addition of a 
20/12/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
